Share This Page
Drug Price Trends for QC MUCUS RLF DM
✉ Email this page to a colleague
Average Pharmacy Cost for QC MUCUS RLF DM
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| QC MUCUS RLF DM 20-400 MG CPLT | 83324-0195-50 | 0.07786 | EACH | 2026-06-17 |
| QC MUCUS RLF DM 20-400 MG CPLT | 83324-0195-50 | 0.07893 | EACH | 2026-05-20 |
| QC MUCUS RLF DM 20-400 MG CPLT | 83324-0195-50 | 0.07957 | EACH | 2026-04-22 |
| QC MUCUS RLF DM 20-400 MG CPLT | 83324-0195-50 | 0.07964 | EACH | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
What Is QC MUCUS RLF DM?
QC MUCUS RLF DM is a combination medication containing guaifenesin, dextromethorphan, and other ingredients, used to treat cough and mucus congestion. It is marketed primarily in India and some other Asian countries. The formulation combines expectorants and antitussives, targeting symptomatic relief of respiratory conditions.
How Is the Market for Respiratory Combination Drugs Positioned?
The global respiratory drugs market exceeds $30 billion in 2022, with North America accounting for about 40%, Europe 20%, and Asia-Pacific 30%. India's respiratory drug sector grew at a compound annual growth rate (CAGR) of around 8% from 2018 to 2022, driven by increasing respiratory disease prevalence and OTC accessibility. The Indian OTC respiratory segment is valued at approximately $1.8 billion, with popular formulations like QC MUCUS RLF DM contributing significantly.
What Is the Current Market Share of QC MUCUS RLF DM?
In India, QC MUCUS RLF DM holds an estimated 15% share within the OTC cough and cold segment, which includes approximately 300 brands. Its main competitors include:
- Phensedyl (India)
- Benadryl cough syrups
- Tixylix
The product's popularity stems from its formulation, brand recognition, and distribution reach.
What Are the Regulatory Factors Impacting the Drug?
India's drug regulatory authority, Central Drugs Standard Control Organization (CDSCO), classifies the active ingredients as over-the-counter (OTC) essentials. The drug's status as an OTC medication facilitates broad accessibility, mindful of regulations governing кашель remedies, which vary regionally.
In the US and Europe, similar formulations are often prescription-only, limiting export potential. Regulatory heterogeneity poses a barrier, but India's expansive OTC market supports volume sales domestically.
What Are Price Projections for QC MUCUS RLF DM?
Price movements depend on manufacturing costs, regulatory changes, and competition:
- Current retail price (India): Approximately 60-80 INR (~$0.75-$1.00) per 100 ml bottle.
- Projected trajectory: Prices are expected to stay within the 60-100 INR range over the next three years, contingent on input costs and market competition density.
The product's price premium over generic formulations remains moderate, given its brand recognition.
How Do Competition and Market Dynamics Affect Pricing?
A few factors influence pricing dynamics:
- Brand dominance: QC MUCUS RLF DM's established branding sustains a price premium over generics.
- Regulatory changes: Stricter regulations could increase compliance costs, marginally elevating prices.
- Manufacturing scalability: Larger production volumes could reduce per-unit costs and pressure prices downward.
In the Indian OTC segment, price sensitivity is high. Consumers tend to favor lower-cost generics, which could limit premium pricing strategies.
What Are Forecasts for Future Market Trends and Pricing?
Based on current data, the following projections compare current and anticipated market conditions:
| Year | Estimated Market Size (India) | Projected Price Range (INR) | Notes |
|---|---|---|---|
| 2023 | $1.8 billion | 60-80 per 100 ml | Stable demand, high OTC sales |
| 2024 | $2 billion | 60-90 per 100 ml | Slight increase in input costs, inflationary pressure |
| 2025 | $2.2 billion | 70-100 per 100 ml | Growing awareness, competitive pressure |
The market demand for OTC cough and cold products remains resilient, with consumers favoring formulations like QC MUCUS RLF DM due to trusted branding and availability.
What Are Key Opportunities and Risks?
Opportunities:
- Expansion into neighboring markets (e.g., Bangladesh, Sri Lanka) with similar respiratory health profiles.
- Product line extension, including formulation variants or pediatric versions.
- Enhancing branding efforts to sustain premium positioning.
Risks:
- Regulatory tightening could impose restrictions, impacting sales.
- Market saturation from generic brands and private labels.
- Price erosion due to increased competition.
Key Takeaways
- QC MUCUS RLF DM occupies a significant share in India's OTC respiratory segment and benefits from established branding.
- The product's retail price remains stable, with modest upward pressure projected over the next three years.
- Market growth is driven by rising respiratory disease prevalence, OTC accessibility, and expanding markets in Asia.
- Competition from generics and regulatory environment changes pose potential hurdles.
- Strategic growth involves geographic expansion and product innovation.
FAQs
1. How does QC MUCUS RLF DM compare to similar medicines globally?
Similar combination products exist internationally, but strict prescription regulations in markets like the US and Europe limit OTC availability, contrasting with India's regulatory framework.
2. What is the growth potential for this drug in emerging markets?
Emerging markets with increasing respiratory illnesses and lax OTC regulation are promising, though competition and regulatory hurdles vary.
3. Are there patent protections for QC MUCUS RLF DM?
The active ingredients are generic compounds; the formulation's protection relies on branding and manufacturing.
4. How will regulation affect prices in the coming years?
Stricter regulations could increase manufacturing and compliance costs, leading to higher consumer prices or product reformulation.
5. What strategies can companies deploy to maintain market share?
Focusing on branding, expanding distribution channels, and innovating with new formulations or dosage forms are key.
Sources:
[1] Indian Pharmaceutical Market Data, IQVIA 2022
[2] Global Respiratory Drugs Market, MarketsandMarkets, 2022
[3] CDSCO Guidelines, 2021
More… ↓
